Oppenheimer Boosts HCA Healthcare (NYSE:HCA) Price Target to $390.00

HCA Healthcare (NYSE:HCA) had its target price hoisted by Oppenheimer from $345.00 to $390.00 in a research report sent to investors on Wednesday morning, Benzinga reports. They currently have an outperform rating on the stock.

A number of other equities research analysts have also commented on HCA. Robert W. Baird assumed coverage on shares of HCA Healthcare in a research note on Thursday, May 30th. They issued an outperform rating and a $396.00 price objective on the stock. Truist Financial boosted their target price on shares of HCA Healthcare from $375.00 to $390.00 and gave the company a buy rating in a research report on Wednesday. Baird R W upgraded shares of HCA Healthcare to a strong-buy rating in a research report on Thursday, May 30th. TD Cowen dropped their target price on shares of HCA Healthcare from $371.00 to $360.00 and set a buy rating on the stock in a research report on Tuesday, April 30th. Finally, Wells Fargo & Company boosted their target price on shares of HCA Healthcare from $303.00 to $315.00 and gave the company an equal weight rating in a research report on Thursday, March 28th. Four analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, HCA Healthcare has a consensus rating of Moderate Buy and an average price target of $339.72.

HCA Healthcare Trading Up 0.6 %

HCA opened at $354.78 on Wednesday. HCA Healthcare has a fifty-two week low of $215.96 and a fifty-two week high of $356.30. The company has a debt-to-equity ratio of 27.11, a current ratio of 1.06 and a quick ratio of 1.02. The firm has a market capitalization of $92.92 billion, a price-to-earnings ratio of 17.69, a PEG ratio of 1.35 and a beta of 1.68. The company’s 50 day moving average price is $330.12 and its two-hundred day moving average price is $323.11.

HCA Healthcare (NYSE:HCA) last posted its quarterly earnings data on Tuesday, July 23rd. The company reported $5.50 EPS for the quarter, beating analysts’ consensus estimates of $4.97 by $0.53. HCA Healthcare had a net margin of 8.40% and a return on equity of 553.13%. The company had revenue of $17.49 billion for the quarter, compared to analyst estimates of $17.05 billion. During the same period in the prior year, the firm posted $4.29 EPS. The company’s quarterly revenue was up 10.3% on a year-over-year basis. As a group, research analysts predict that HCA Healthcare will post 22.44 earnings per share for the current year.

HCA Healthcare Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 16th will be given a dividend of $0.66 per share. The ex-dividend date of this dividend is Monday, September 16th. This represents a $2.64 dividend on an annualized basis and a yield of 0.74%. HCA Healthcare’s dividend payout ratio is presently 13.16%.

Insiders Place Their Bets

In other HCA Healthcare news, EVP Michael S. Cuffe sold 1,600 shares of the stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $309.00, for a total transaction of $494,400.00. Following the completion of the transaction, the executive vice president now owns 34,124 shares in the company, valued at $10,544,316. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, SVP Kathryn A. Torres sold 973 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $312.00, for a total value of $303,576.00. Following the completion of the transaction, the senior vice president now directly owns 22,365 shares in the company, valued at $6,977,880. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael S. Cuffe sold 1,600 shares of the firm’s stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $309.00, for a total transaction of $494,400.00. Following the completion of the transaction, the executive vice president now owns 34,124 shares of the company’s stock, valued at $10,544,316. The disclosure for this sale can be found here. Insiders sold 12,397 shares of company stock worth $3,921,929 over the last quarter. 1.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On HCA Healthcare

Institutional investors and hedge funds have recently bought and sold shares of the stock. MFA Wealth Advisors LLC purchased a new stake in HCA Healthcare in the second quarter valued at approximately $27,000. Unique Wealth Strategies LLC purchased a new stake in HCA Healthcare in the second quarter valued at approximately $28,000. Bangor Savings Bank raised its stake in HCA Healthcare by 112.5% in the second quarter. Bangor Savings Bank now owns 85 shares of the company’s stock valued at $27,000 after purchasing an additional 45 shares in the last quarter. GPS Wealth Strategies Group LLC raised its stake in shares of HCA Healthcare by 284.0% during the second quarter. GPS Wealth Strategies Group LLC now owns 96 shares of the company’s stock worth $31,000 after acquiring an additional 71 shares in the last quarter. Finally, Atlantic Edge Private Wealth Management LLC purchased a new position in shares of HCA Healthcare during the fourth quarter worth approximately $27,000. 62.73% of the stock is owned by hedge funds and other institutional investors.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.